A Shift in Sentiment

At ECR 2025, the conversation around AI in medical imaging felt meaningfully different from just a year ago. Where skepticism about immediate value was still prominent at the previous congress, this year suggested a shift: the field may be moving beyond the inflection point, with adoption starting to gain real momentum.

From Evidence to Implementation

This shift is grounded in increasingly visible clinical impact. Presentations on the MASAI trial in mammography screening in Sweden and Vestre Viken hospital’s AI-powered fracture detection pathway in Norway contributed to a growing perception of real-world impact in clearly defined use cases.

At the same time, discussions with thought leaders reflected a broader change in mindset. The central question is no longer whether AI will play a role, but how it should be implemented in practice.

What Is Changing in the Market

Market dynamics are evolving, with consolidation underway and leading vendors appearing well-funded. In parallel, several significant clinical implementations have either been announced or are expected in the near term.

At the level of deployment, the question of how AI solutions are best accessed remains open. The choice between platform-based distribution and direct vendor integration continues to be debated, particularly as some vendors expand their portfolios and aim to cover a broader range of clinical applications.

As adoption grows, so does the focus on performance in real-world settings. Post-market surveillance and continuous monitoring featured prominently in both sessions and conversations, indicating increasing experience with deployed systems and a more pressing need for reliable performance over time.

Deeper integration into clinical workflows is also progressing. AI is becoming more embedded in reporting and follow-up processes, with several platforms and pathway-oriented vendors introducing new offerings that attracted strong interest from customers.

At the same time, reimbursement and monetization models are evolving. Selective contracts, NHS reimbursement schemes and out-of-pocket approaches illustrate that there is no single path to commercial success. Instead, vendors are identifying specific routes to sustainably capture value.

An Inflection Point?

Taken together, these developments suggest a field that is beginning to transition into broader implementation. After years of slower-than-expected adoption, the key question remains: has the inflection point now truly been crossed – and will AI-driven value creation in medical imaging accelerate from here?